Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Zn-Telomir · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| Phase I Dose Escalation | EXPERIMENTAL | Participants receive oral Zn-Telomir once daily on Days 1-14 of each 28-day cycle at assigned cohort dose levels of 50 mg, 100 mg, 150 mg, 200 mg, 300 mg, or 400 mg. Number of cycles will vary based on dose level and tolerability. |
| Phase II Dose Expansion | EXPERIMENTAL | Participants receive oral Zn-Telomir at the recommended Phase II dose once daily on Days 1-14 of each 28-day cycle for up to 4 cycles, if tolerated. |
| Name | Type | Description |
|---|---|---|
| Zn-Telomir | DRUG | Zn-Telomir is an oral small molecule that inhibits iron-dependent KDM enzymes, reduces tumor DNA methylation, and kills cancer cells in an iron-dependent manner - targeting epigenetic and metal homeostasis drivers of cancer cell survival. |
Inclusion Criteria: 1. Clinically defined histologically or cytologically confirmed triple-negative breast cancer (TNBC) 2. Locally advanced unresectable or metastatic disease 3. Must have completed prior anticancer therapy discontinued for a least 28 days 4. Disease progression after prior systemi...
Zn-Telomir is an investigational small molecule being developed for the treatment of advanced or metastatic Triple-Negative Breast Cancer (TNBC). It is currently in Phase 1 clinical development as an oral monotherapy for patients with this condition.
Zn-Telomir is being developed by Telomir Pharmaceuticals, Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol TELO.
Zn-Telomir is in Phase 1 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. A Phase 1 trial is currently planned but has not yet started recruiting participants.
Zn-Telomir is associated with one clinical trial, identified as NCT07581314. This is a Phase 1 study titled 'Oral Zn-Telomir Monotherapy in Patients With Advanced or Metastatic Triple-Negative Breast Cancer (TNBC)', with an enrollment target of 76 participants.
Zn-Telomir is the drug name used in the clinical trial context, and it is developed by Telomir Pharmaceuticals. The name 'Telomir' is part of the company name, but the drug itself is specifically referred to as Zn-Telomir in the trial.